PharmaLinkFHI Renews License Agreement with Phase Forward; Company Relies on Phase Forward's InForm™ EDC Solution to Accelerate Clinical Data Collection and Analysis

Business Wire, March 23, 2006

WALTHAM, Mass. -- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced PharmaLinkFHI (PharmaLink), a leading electronic clinical research organization (eCRO), has signed a three-year license agreement to extend its use of Phase Forward's InForm(TM) Web-based solution for electronic data capture (EDC). A longtime strategic partner, PharmaLink plans to continue to leverage Phase Forward's InForm as one of its primary EDC tools.

With the InForm solution, PharmaLink can help its clients quickly and efficiently access, analyze and report critical clinical data. Because InForm offers enterprise-level scalability - to thousands of sites and tens of thousands of patients - and extensive functionality in an intuitive user interface, clinical development staff can do more faster and with greater accuracy.

"As the leading eCRO conducting all of our trials in EDC, we realized InForm's benefits long ago and have shared many successful implementations with Phase Forward during our strong, six-year partnership," said Richard Staub, president and chief operating officer, PharmaLink. "Because of the increased efficiency it affords, we integrated InForm with our Web-based clinical trial management and reporting system (CTMS), InfoLink. By leveraging the data visibility afforded by our technology platform, combined with our high efficiency clinical processes, we've reduced the time from Last Patient/Last Visit to database lock to between three to eight working days. In addition to its functionality, Phase Forward's worldwide experience will be particularly critical to PharmaLink as we anticipate future global engagements."

"As a firm that's focused on real-time clinical trial management, PharmaLink is at the vanguard of technology adoption," said Bob Weiler, president and chief executive officer, Phase Forward. "The company has pioneered best practices to ensure quality and provide high levels of visibility into the clinical trial process. We are pleased to be working with such a committed partner."

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InForm(TM)), clinical data management (Clintrial(TM)), clinical trials signal detection (CTSD(TM)), strategic pharmacovigilance (WebVDME(TM) and Signal Management), adverse event reporting (Clintrace(TM)) and applied data standards (WebSDM). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 230 organizations and regulatory agencies worldwide including: AstraZeneca, Biogen Idec, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, Food and Drug Administration, GlaxoSmithKline, Guidant, Merck, U.K. Medicines and Healthcare Products Regulatory Agency, National Institutes of Health, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute and Serono. Additional information about Phase Forward is available at www.phaseforward.com.

About PharmaLinkFHI

PharmaLink is a new breed of clinical research organization managing Phase I-IV clinical trials and post-marketing programs online in real time. From protocol development through final clinical study report, PharmaLink integrates deep clinical know-how with industry leading technologies, engaging the entire clinical team with actionable intelligence for more confident decision-making and risk management.

Biopharmaceutical and device manufacturers look to PharmaLink's proven approach to support and streamline the product development process. Reflecting its focus on quality customer service, PharmaLink has been certified by Underwriters Laboratories on meeting global quality standards (ISO 9001:2000). PharmaLink is affiliated with Durham based Family Health International (www.fhi.org), a not for profit public health research and services organization with offices in over 40 countries. For more information on PharmaLink, visit our web site at www.pharmalinkfhi.com.

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance of Phase Forward's products and services, future business and operations plans of a Phase Forward customer, and the ability of Phase Forward's customers to realize benefits from the use of Phase Forward's products and services. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward's customers to realize benefits from the use of its products and services, and the possibility that customers' needs or plans may change over time. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.